QCÒÇÆ÷¼¼ÊõÔ±/¹¤³Ìʦ 6000-7999 ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐƸ > QCÒÇÆ÷¼¼ÊõÔ±/¹¤³Ìʦ

QCÒÇÆ÷¼¼ÊõÔ±/¹¤³Ìʦ

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2022-06-06±»ä¯ÀÀ£º676´Î

6000-7999

²»ÏÞ / ´óר / ÐÔ±ð²»ÏÞ / 5 / ²»ÏÞµ½¸Ú

½­ËÕ-Ì©ÖÝ £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© ÉÏ°à·Ïß²éѯ

ÕÐƸ5

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíȨÒ棬¾¯ÌèÐé¼ÙÕÐƸ,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

¸ÚλְÔð£º1.
ÅäºÏ¹¤ÒÕÑéÖ¤ÑùÆ··ÖÎö£»

²úÆ·µÄ·ÅÐУ¬Îȶ¨ÐÔÑùÆ·µÄ¼ì²â£»

2.
²ÎÓë·ÖÎö·½·¨ÑéÖ¤·½°¸µÄÆð²Ý£¬·½·¨Ñé֤ʵÑéʵʩ£¬Êý¾Ý±¨¸æ»ã×Ü£»

3.
É豸µÄÑéÖ¤ÈÕ³£µÄά»¤±£Ñø£»

4.
ʵÑéÊÒÏà¹ØÎļþµÄÉý°æ±¾Æð²Ý¡£
¸ÚλҪÇó£º1.
»¯Ñ§Ò©Ñ§ÉúÎïµÈÏà¹Øרҵ£¬´óר¼°ÒÔÉÏѧÀú£»

2.
¶Ô¸ßЧҺÏà×ÏÍâ·Ö¹â¹â¶È¼Æëϸ¹ÜµçÓ¾µÄÓÐʹÓûù´¡£
»3.
ÊìϤÖйúÒ©µäGMP·¨¹æºÍ·ÖÎö·½·¨ÑéÖ¤£»

4.
ÓжԵ¥¿¹ÀàÖÆÆ·¼ì²âÏà¹Ø¾­ÑéÕßÓÅÏÈ¡£

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàƽ·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖƱ¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖصãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøм²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • ½­ËÕ-Ì©ÖÝ
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
2¸öÕÐƸְλ
ְλÃû³Æ£ºQCÒÇÆ÷¼¼ÊõÔ±/¹¤³Ìʦ
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆְλ